EAM Investors’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-182,509
Closed -$650K 374
2025
Q4
$650K Hold
182,509
0.07% 244
2025
Q3
$637K Sell
182,509
-13,328
-7% -$45.7K 0.07% 239
2025
Q2
$401K Buy
+195,837
New +$490K 0.06% 218

Other funds holding STLN

EAM Investors's STLN Position: Q1 2026 in Review

EAM Investors sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2026, closing a stake of 182,509 shares — an estimated $650K sold.

EAM Investors first reported a position in STLN in Q2 2025 and held it in 3 quarters. The position peaked at $650K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • EAM Investors reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
  • EAM Investors sold 182,509 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $650K.
  • EAM Investors first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2025 and held it in 3 quarters.
  • EAM Investors's Starling Oncology Institute, Inc. Common Stock position peaked at $650K in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.